tetano
Editor, Senior Moderator
Viruses. 2015 Jul 8;7(7):3768-3788.
[h=1]Cloned Defective Interfering Influenza RNA and a Possible Pan-Specific Treatment of Respiratory Virus Diseases.[/h] Dimmock NJ[SUP]1[/SUP], Easton AJ[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Defective interfering (DI) genomes are characterised by their ability to interfere with the replication of the virus from which they were derived, and other genetically compatible viruses. DI genomes are synthesized by nearly all known viruses and represent a vast natural reservoir of antivirals that can potentially be exploited for use in the clinic. This review describes the application of DI virus to protect from virus-associated diseases in vivo using as an example a highly active cloned influenza A DI genome and virus that protects broadly in preclinical trials against different subtypes of influenza A and against non-influenza A respiratory viruses. This influenza A-derived DI genome protects by two totally different mechanisms: molecular interference with influenza A replication and by stimulating innate immunity that acts against non-influenza A viruses. The review considers what is needed to develop DI genomes to the point of entry into clinical trials.
[h=4]KEYWORDS:[/h] antivirals; defective interfering RNA; influenza virus; prophylaxis; respiratory disease; therapy; treatment
PMID: 26184282 [PubMed - as supplied by publisher] Free full text
[h=1]Cloned Defective Interfering Influenza RNA and a Possible Pan-Specific Treatment of Respiratory Virus Diseases.[/h] Dimmock NJ[SUP]1[/SUP], Easton AJ[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Defective interfering (DI) genomes are characterised by their ability to interfere with the replication of the virus from which they were derived, and other genetically compatible viruses. DI genomes are synthesized by nearly all known viruses and represent a vast natural reservoir of antivirals that can potentially be exploited for use in the clinic. This review describes the application of DI virus to protect from virus-associated diseases in vivo using as an example a highly active cloned influenza A DI genome and virus that protects broadly in preclinical trials against different subtypes of influenza A and against non-influenza A respiratory viruses. This influenza A-derived DI genome protects by two totally different mechanisms: molecular interference with influenza A replication and by stimulating innate immunity that acts against non-influenza A viruses. The review considers what is needed to develop DI genomes to the point of entry into clinical trials.
[h=4]KEYWORDS:[/h] antivirals; defective interfering RNA; influenza virus; prophylaxis; respiratory disease; therapy; treatment
PMID: 26184282 [PubMed - as supplied by publisher] Free full text